Preface: the strongest, guideline-consistent evidence supports two low-risk interventions as the foundation of any “skinspan” programme: daily broad-spectrum sunscreen (the only intervention shown in RCT to retard clinical photoaging over years) and[1][2] topical retinoids/tretinoin (robust RCT and network meta-analysis evidence for wrinkles, texture and pigmentation).[3][4][5] Photobiomodulation (red/near-infrared LED) has moderate-certainty evidence for modest wrinkle/texture improvement and a strong safety record but no long-term or hard-outcome data.[6][7][8] Senolytics (dasatinib+quercetin), NAD⁺ precursors and other “root-cause” geroscience approaches remain experimental / research-only for skin, resting largely on preclinical and mechanistic data.[9][10][11] Note the term “skinspan” is a recently coined framework (Mayo Clinic Proceedings, 2025), not an established diagnostic entity.[12]



1. Scope

– Covered: Evidence-based and emerging interventions to prevent and treat photoaging and to extend “skinspan” (the healthspan of skin) in adults attending a private UK longevity clinic — photoprotection, topical retinoids, topical/oral antioxidants (niacinamide, vitamin C), photobiomodulation (PBM/LED), and geroscience-based approaches (senolytics, NAD⁺ modulation).

– Not covered: Ablative/energy-based aesthetic resurfacing (fractional laser, radiofrequency, microneedling), injectables (toxin, fillers), management of skin malignancy or actinic keratosis as primary indications, and paediatric skin.

– Positioning: All content is adjunctive to conventional primary and secondary dermatology care. Suspicious lesions, established skin cancer, or dermatological disease require standard referral, not longevity-clinic management.



2. Background and pathophysiology

Skin ageing reflects intrinsic (chronological) and extrinsic (exposome) processes converging on shared hallmarks of ageing.[13][12]

– Extrinsic (photoaging): Chronic UV — the dominant modifiable driver — causes mtDNA damage, ROS generation, matrix metalloproteinase (MMP) upregulation with collagen/elastin degradation (solar elastosis), DNA damage and epigenetic changes, and induction of the senescence-associated secretory phenotype (SASP).[13][12][14]

– Intrinsic: Cellular senescence (p16^INK4a/p53), telomere attrition, epigenetic alteration, mitochondrial dysfunction, loss of proteostasis, stem-cell exhaustion and “inflammaging”.[12][9][15]

– Mechanisms targeted by interventions:

– Sunscreen — prevents the upstream UV insult; RCT-adjacent molecular data show it blunts UV-induced epigenetic age acceleration and preserves DNA-repair/immune pathways.[14]

– Retinoids — bind nuclear retinoic-acid receptors → increased procollagen, reduced MMP-1, normalised epidermal differentiation.[4][5]

– PBM — red/NIR photons absorbed by mitochondrial cytochrome-c oxidase → increased ATP, modulated ROS/Ca²⁺, TGF-β1 activation, increased procollagen and reduced MMP-1.[16][17][18]

– Niacinamide — restores NAD⁺ pool and mitochondrial energetics, DNA repair, barrier support.[19][20][21]

– Preclinical only (clearly separated): Senolytic clearance of senescent dermal fibroblasts (D+Q) increasing collagen density and suppressing SASP — demonstrated in vitro and in a mouse–human skin chimera, not in human trials. Fibroblast metabolic reprogramming and EV-based rejuvenation are in-vitro/animal concepts only.[10][9]



3. Evidence base and grading

Intervention / outcome	Evidence summary	GRADE certainty	Key limitations	Strength of recommendation
Daily broad-spectrum sunscreen → slows clinical photoaging	1 large community RCT (n=903, 4.5 yr): 24% less photoaging vs discretionary use (OR 0.76, 95% CI 0.59–0.98) [1]; supportive prospective RCT across phototypes II–VI [22]	Moderate	Single pivotal RCT; older low-UVA formulation; some missing data	Strong recommendation (offer)
Topical retinoids/tretinoin → fine wrinkles, texture, pigmentation	Network MA of 23 RCTs (n=3905): tretinoin/retinol/isotretinoin improve fine wrinkles; tretinoin best safety profile [3]; FDA-approved for photoaging palliation [4], [5]	Moderate–High	Irritation risk unblinds trials; effect sizes modest; needs continued use	Strong recommendation (offer, on-label in some formulations)
PBM (red/NIR LED) → wrinkle/texture/elasticity	Systematic review + MA of RCTs (SMD −3.45; I²=33%) [6]; split-face single-blind [17]; expert consensus [7]	Low–Moderate	Small samples, short follow-up, heterogeneous parameters, industry involvement, no hard endpoints	Conditional recommendation (consider)
Topical niacinamide → tone/texture/barrier	Multiple small clinical trials; consistent benefit, well tolerated [20], [23]	Low	Small RCTs, surrogate endpoints, formulation heterogeneity	Conditional recommendation (consider)
Oral nicotinamide → skin outcomes	RCT evidence is for AK/NMSC chemoprevention (ONTRAC: 23% fewer NMSC) [21], not photoaging per se	Moderate (for NMSC) / Very low (photoaging)	Indirect for skinspan; benefit is oncologic not cosmetic	Photoaging: only in research; NMSC prevention: per dermatology guidance
Oral β-carotene → photoaging	RCT arm within Nambour trial: no effect [1]	Moderate	—	Recommend against (for this indication)
Senolytics (D+Q) → skin rejuvenation	In-vitro + mouse–human chimera only [10]; systemic geroscience rationale [11]	Very low	No human skin RCTs; extrapolation from preclinical	Only in research

– Publication bias: Likely material for PBM and cosmeceuticals (small positive industry-linked studies; device heterogeneity). Sunscreen and retinoid evidence is more robust and less affected.

– Indirectness caveat: Most endpoints are surrogate/cosmetic (wrinkle scores, profilometry, biomarkers). Do not infer systemic longevity or hard health benefit from skin surrogates — that linkage is not established.[12]



4. Patient selection and indications

Who may benefit (inclusion):

– Adults of any age seeking prevention — sunscreen is universal and lifelong.[1][2]

– Adults ~30+ with visible/early photoaging (fine wrinkles, dyspigmentation, roughness), Fitzpatrick I–VI, wanting active treatment — retinoids ± niacinamide ± PBM.[3][22]

– Patients preferring non-pharmacological/low-irritation options, or unable to tolerate retinoids — PBM or niacinamide.[6][23]

Exclusion / high-risk / specialist input:

– Retinoids: pregnancy and those planning pregnancy (Category C; avoid); breastfeeding — caution; active dermatitis/rosacea flares; concurrent photosensitising therapy.[24]

– PBM: photosensitising drugs/conditions, active cutaneous malignancy or premalignant lesions in the field (treat/refer first), history of light-triggered disorders (e.g. porphyria, SLE) — specialist advice; ocular protection required.

– Any suspicious pigmented or non-healing lesion → refer under standard 2-week-wait pathways before cosmetic intervention.

Regulatory/ethical status (UK):

– On-label: Prescription tretinoin/topical retinoids for photodamage; sunscreens as cosmetic products. Home/professional LED devices are generally marketed as cosmetic/wellness (not MHRA-regulated therapeutic claims).

– Off-label / cosmeceutical: oral nicotinamide for photoaging; PBM for “rejuvenation” beyond consensus-supported indications.[7]

– Research-only: senolytics, NAD⁺-precursor supplements and other geroscience agents for skin — use only within trial frameworks or, if at all, with explicit written informed consent documenting the absence of human efficacy data.[10][11]



5. Assessment and baseline work-up

– History: Fitzpatrick phototype, cumulative/recreational UV and sunbed exposure, smoking, personal/family skin-cancer history, current photosensitising medication, pregnancy status, prior aesthetic procedures, skincare regimen.

– Examination & scoring: Validated tools — Griffiths photonumeric photoaging scale, Fitzpatrick wrinkle score, Glogau classification; standardised (ideally cross-polarised/UV) photography at fixed settings.

– Objective skin metrics (optional, for follow-up): profilometry/OCT for wrinkle depth, corneometry (hydration), cutometry (elasticity), colorimetry/melanin index.[17][25][22]

– Baseline investigations: No routine bloods needed for sunscreen/retinoid/PBM. Full-body skin examination to exclude malignancy/premalignancy before starting. Only consider bloods if a systemic agent is contemplated within a trial.

– Risk stratification:

– Low risk: healthy adult, no lesions, no photosensitisers → sunscreen ± retinoid ± PBM.

– Moderate: significant photodamage, past NMSC/AK → coordinate with dermatology; nicotinamide chemoprevention per dermatology guidance.[21]

– High: immunosuppressed, prior melanoma, photosensitising disease, pregnancy → specialist-led; avoid off-label agents.

– Documentation: phototype, baseline photoaging score, standardised photographs, exposome risk factors, consent (including off-label status). Ageing “biomarkers” (e.g. skin epigenetic-age tools) are research metrics only — record as such if used.[14]



6. Dosing regimens and practical implementation

Supported by robust human data:

– Sunscreen: broad-spectrum, high UVA protection, SPF ≥30 (ideally 50), applied daily to face/neck/dorsal hands at ~2 mg/cm² (≈¼ tsp face+neck), reapplied with exposure. Daily (not discretionary) use is the RCT-validated regimen.[1][2]

– Topical tretinoin: start 0.025% cream nightly (or alternate nights) to clean dry skin, pea-sized amount, avoiding periorbital/perioral creases; titrate to 0.05% as tolerated over weeks (“start low, go slow”). Benefit accrues over ~3–6 months and requires continued use; concurrent sunscreen mandatory (retinoids increase UVB penetration). Tretinoin-precursor formulations offer comparable efficacy with less erythema for irritation-prone patients.[24][5][26]

– Niacinamide (topical): 2–5% daily, well tolerated, combinable with retinoids.[23][20]

Moderate/low-certainty — consider with realistic expectations:

– PBM/red LED: red light ~630–660 nm (± NIR ~830–850 nm); fluence broadly ~4–10 J/cm² at low irradiance (bioinhibition possible at excess dose — Arndt–Schulz relationship). Typical protocols: ~20–30 min sessions, 2–5×/week for 4–12 weeks, spacing sessions ≥~72 h reflects one proposed cellular-recovery model. Eye protection; use calibrated devices — tanning-salon “red light” is not endorsed.[16][25][27]

Extrapolated / require caution (research context):

– Senolytics (D+Q), NAD⁺ precursors (NR/NMN), oral nicotinamide for photoaging: no validated dermatologic dosing; do not prescribe outside trials. (Oral nicotinamide 500 mg twice daily is the NMSC-chemoprevention dose, a distinct oncologic indication.)[10][11][21]



7. Monitoring, safety and follow-up

– Monitoring parameters: tolerability (erythema, peeling, dryness, stinging — especially retinoids); adherence; standardised photographs and repeat photoaging score at follow-up; watch for any new/changing lesions.

– Timepoints: review at 6–12 weeks (tolerability, titration), 3–6 months (efficacy assessment), then 6–12-monthly for maintenance and skin surveillance.

– Adverse effects:

– Retinoids: very common mild local irritation/”retinoid dermatitis,” photosensitivity; mitigated by low starting dose, nightly application, moisturiser, sunscreen. No good evidence for systemic effects from topical use.[24][4]

– Sunscreen: rare contact/photocontact reactions.

– PBM: generally very well tolerated; erythema is the commonest, self-limiting effect; systematic review found no oncologic safety signal and red-light PBM does not induce DNA damage. Serious events are rare; ocular exposure is the main avoidable hazard.[18][7][8]

– Action on abnormal findings: intolerable irritation → reduce frequency/concentration or switch to precursor formulation; suspicious lesion → stop cosmetic treatment and refer; no response by 6 months → reassess diagnosis/adherence.

– Interactions: retinoid + other topical actives (AHAs, benzoyl peroxide) → additive irritation; retinoid/PBM + systemic photosensitisers (tetracyclines, thiazides, amiodarone, St John’s wort) → caution.

– Special populations: Pregnancy/breastfeeding — avoid topical retinoids; sunscreen and physical photoprotection preferred; PBM data insufficient — avoid off-label use. Frailty/elderly — favour low-irritation regimens (sunscreen, niacinamide, PBM); simplify. Renal/hepatic impairment — no concern for topical photoaging agents; relevant only if systemic geroscience agents were used in research.



8. Contraindications and cautions

– Absolute: topical retinoids in pregnancy/planned pregnancy; any active or suspected cutaneous malignancy/premalignancy in the treatment field until assessed/treated; PBM directly to the unprotected eye.[24]

– Relative / specialist advice: photosensitising disease (porphyria, lupus), photosensitising medication, immunosuppression or prior melanoma, active inflammatory dermatoses, breastfeeding.

– Harm likely to outweigh benefit with current evidence: systemic senolytics or NAD⁺ precursors prescribed for cosmetic/skin indications outside a trial (unknown efficacy, real drug toxicity for dasatinib); unsupervised tanning-salon “red light therapy”; β-carotene for photoaging.[10][11][27][1]



9. Practical management scenarios

Scenario A — Middle-aged patient with multiple cardiometabolic risk factors seeking skin longevity.

– Recommendation: Offer foundational regimen (Strong).

– Assessment: phototype, photoaging score, full skin check, medication review.

– Shared decision/consent: emphasise sunscreen + retinoid as the evidence-based core; PBM/niacinamide as optional adjuncts with modest, mainly cosmetic benefit.

– Initiation: daily SPF 50 broad-spectrum; tretinoin 0.025% nightly, titrate; ± topical niacinamide.[1][3][5]

– Monitoring: 6–12 weeks for tolerability, 6 months for efficacy; annual skin surveillance.

– Escalate/stop: refer any suspicious lesion; reassess if intolerant.

Scenario B — Older, frail patient with multimorbidity.

– Recommendation: Consider simplified, low-irritation regimen (Conditional); avoid off-label systemic agents (Recommend against).

– Prioritise daily sunscreen and emollient; consider niacinamide or PBM rather than potentially irritating retinoids; deprioritise cosmetic goals against polypharmacy and skin fragility.

– Monitor barrier integrity, adherence; low threshold to simplify.

Scenario C — Adjunct in a patient already under dermatology/oncology care (e.g. prior NMSC/AK).

– Recommendation: Offer photoprotection; coordinate other agents with the specialist.

– Reinforce daily broad-spectrum sunscreen; oral nicotinamide 500 mg BD for NMSC chemoprevention is a dermatology-led decision, not a skinspan indication; PBM appears oncologically safe but agree the plan with the treating team. Avoid initiating retinoids/energy treatments over untreated lesions.[21][8]

Scenario D — Patient requesting senolytics/NAD⁺ therapy “for skin ageing.”

– Recommendation: Only in research (Conditional against outside trials).

– Explain that human skin evidence is preclinical only; redirect to the validated core regimen; offer signposting to registered trials/registries if genuinely interested.[10][11]



10. Research gaps and future directions

– Hard vs surrogate outcomes: Whether improving skin surrogates (wrinkles, elasticity, epigenetic skin age) translates to any systemic health/longevity benefit is unproven — a central “skinspan” uncertainty.[12][14]

– PBM standardisation: optimal wavelength, fluence, irradiance, treatment frequency and durability of effect; independent, adequately powered, long-follow-up RCTs with active controls are needed.[6][7]

– Senolytics for skin: first-in-human, placebo-controlled skin trials of topical/systemic D+Q or fisetin with SASP and histological endpoints before any clinical use.[10][11]

– NAD⁺ modulation: RCTs testing topical/oral nicotinamide and NAD⁺ precursors specifically on validated photoaging endpoints (current strong data are oncologic, not cosmetic).[20][21]

– Diverse populations: most retinoid/photoprotection RCTs under-represent skin of colour and phototypes IV–VI.[3][22]

– Registries: any off-label longevity dermatology practice should ideally be captured in prospective registries or trial frameworks to build the missing evidence base.

References

1. Sunscreen and Prevention of Skin Aging: A Randomized Trial. Hughes MC, Williams GM, Baker P, Green AC. Annals of Internal Medicine. 2013;158(11):781-90. doi:10.7326/0003-4819-158-11-201306040-00002.
2. Daily photoprotection to prevent photoaging. Krutmann J, Schalka S, Watson REB, Wei L, Morita A. Photodermatology, Photoimmunology & Photomedicine. 2021;37(6):482-489. doi:10.1111/phpp.12688.
3. Comparative Efficacy of Topical Interventions for Facial Photoaging: A Network Meta-Analysis. Lin L, Chen X, Liu C, et al. Scientific Reports. 2025;15(1):26889. doi:10.1038/s41598-025-12597-0.
4. An Updated Review of Topical Tretinoin in Dermatology: From Acne and Photoaging to Skin Cancer. Balado-Simó P, Morgado-Carrasco D, Gómez-Armayones S, et al. Journal of Clinical Medicine. 2025;14(22):7958. doi:10.3390/jcm14227958.
5. Treatment of Photoaging. Stern RS. The New England Journal of Medicine. 2004;350(15):1526-34. doi:10.1056/NEJMcp023168.
6. Utilization of light‐emitting diodes for skin therapy: Systematic review and meta‐analysis. Ngoc LTN, Moon JY, Lee YC. Photodermatology, Photoimmunology & Photomedicine. 2023;39(4):303-317. doi:10.1111/phpp.12841.
7. Evidence-Based Consensus on the Clinical Application of Photobiomodulation. Maghfour J, Mineroff J, Ozog DM, et al. Journal of the American Academy of Dermatology. 2025;:S0190-9622(25)00659-0. doi:10.1016/j.jaad.2025.04.031.
8. Photobiomodulation: A Systematic Review of the Oncologic Safety of Low-Level Light Therapy for Aesthetic Skin Rejuvenation. Glass GE. Aesthetic Surgery Journal. 2023;43(5):NP357-NP371. doi:10.1093/asj/sjad018.
9. Recent Advances in Dermal Fibroblast Senescence and Skin Aging: Unraveling Mechanisms and Pioneering Therapeutic Strategies. Nan L, Guo P, Hui W, Xia F, Yi C. Frontiers in Pharmacology. 2025;16:1592596. doi:10.3389/fphar.2025.1592596.
10. Combined Dasatinib and Quercetin Treatment Contributes to Skin Rejuvenation Through Selective Elimination of Senescent Cells in Vitro and in Vivo. Takaya K, Kishi K. Biogerontology. 2024;25(4):691-704. doi:10.1007/s10522-024-10103-z.
11. Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement. Forman DE, Kuchel GA, Newman JC, et al. Journal of the American College of Cardiology. 2023;82(7):631-647. doi:10.1016/j.jacc.2023.05.038.
12. SkinspanTM: A Healthy Longevity Framework for Skin Aging. Wyles SP, Maredia HS, Ansaf RB, et al. Mayo Clinic Proceedings. 2025;100(11):1976-1991. doi:10.1016/j.mayocp.2025.07.027.
13. Skin Aging and Mitochondrial Dysfunction: Structural Changes, Mechanistic Insights, and Therapeutic Perspectives. de Afonso Bonotto NC, Musachio E, Felin GD, et al. Oxidative Medicine and Cellular Longevity. 2026;2026(1):e5140711. doi:10.1155/omcl/5140711.
14. Sunscreen Application Substantially Mitigates Molecular Perturbations Induced by Repetitive UV Exposure and Maintains Healthy Skin. Bienkowska A, Boedewadt J, Elsbroek L, et al. Scientific Reports. 2026;16(1):4326. doi:10.1038/s41598-026-37232-4.
15. The Role of Cellular Senescence in Skin Aging and Age-Related Skin Pathologies. Chin T, Lee XE, Ng PY, Lee Y, Dreesen O. Frontiers in Physiology. 2023;14:1297637. doi:10.3389/fphys.2023.1297637.
16. Reverse skin aging signs by red light photobiomodulation. Couturaud V, Le Fur M, Pelletier M, Granotier F. Skin Research and Technology : Official Journal of International Society for Bioengineering and the Skin (ISBS) [And] International Society for Digital Imaging of Skin (ISDIS) [And] International Society for Skin Imaging (ISSI). 2023;29(7):e13391. doi:10.1111/srt.13391.
17. Regulation of Skin Collagen Metabolism in Vitro Using a Pulsed 660 Nm LED Light Source: Clinical Correlation With a Single-Blinded Study. Barolet D, Roberge CJ, Auger FA, Boucher A, Germain L. The Journal of Investigative Dermatology. 2009;129(12):2751-9. doi:10.1038/jid.2009.186.
18. Photobiomodulation CME Part I: Overview and Mechanism of Action. Maghfour J, Ozog DM, Mineroff J, et al. Journal of the American Academy of Dermatology. 2024;91(5):793-802. doi:10.1016/j.jaad.2023.10.073.
19. Nicotinamide Prevents UVB- And Oxidative Stress‒Induced Photoaging in Human Primary Keratinocytes. Tan CYR, Tan CL, Chin T, et al. The Journal of Investigative Dermatology. 2022;142(6):1670-1681.e12. doi:10.1016/j.jid.2021.10.021.
20. Mechanistic Basis and Clinical Evidence for the Applications of Nicotinamide (Niacinamide) to Control Skin Aging and Pigmentation. Boo YC. Antioxidants (Basel, Switzerland). 2021;10(8):1315. doi:10.3390/antiox10081315.
21. Sunproofing from within: A deep dive into oral photoprotection strategies in dermatology. Hartmann D, Valenzuela F. Photodermatology, Photoimmunology & Photomedicine. 2024;40(4):e12985. doi:10.1111/phpp.12985.
22. Impact on Facial Skin Aging Signs of a 1-Year Standardized Photoprotection Over a Classical Skin Care Routine in Skin Phototypes II-VI Individuals: A Prospective Randomized Trial. Flament F, Mercurio DG, Catalan E, et al. Journal of the European Academy of Dermatology and Venereology : JEADV. 2023;37(10):2090-2097. doi:10.1111/jdv.19230.
23. Exploring Niacinamide as a Multifunctional Agent for Skin Health and Rejuvenation. Kapoor K, S S, Begum RF, S AS, N A. Current Pharmaceutical Biotechnology. 2025;:CPB-EPUB-151051. doi:10.2174/0113892010402025250922222646.
24. Topical treatments and skin‐resurfacing techniques for skin ageing. Wei Qiang Chng, Miny Samuel, Khimara Naidoo, et al. Cochrane Database of Systematic Reviews. 2021. doi:10.1002/14651858.CD014391.
25. Clinical Application of a New Near-Infrared Light-Emitting Diode With Broader Spectrum for Skin Rejuvenation and Hair Growth Enhancement. Kim JH, Seo J, Koh A, Kim M, Heo CY. Aesthetic Plastic Surgery. 2026;50(7):2743-2751. doi:10.1007/s00266-025-05476-6.
26. Biomarkers of Tretinoin Precursors and Tretinoin Efficacy in Patients With Moderate to Severe Facial Photodamage: A Randomized Clinical Trial. Chien AL, Kim DJ, Cheng N, et al. JAMA Dermatology. 2022;158(8):879-886. doi:10.1001/jamadermatol.2022.1891.
27. Position Statement:Red Light Therapy at Tanning Salons. American Academy of Dermatology (2023).